Shingles Vaccine Age Recommendations
There is no maximum age limit for receiving the shingles vaccine—adults aged 50 years and older should receive the recombinant zoster vaccine (Shingrix/RZV) regardless of how old they are, with vaccination strongly recommended starting at age 50 for immunocompetent adults. 1
Key Age-Based Recommendations
Starting Age: 50 Years and Older
- Recombinant zoster vaccine (RZV/Shingrix) is strongly recommended for all immunocompetent adults aged ≥50 years 1
- The vaccine demonstrates 97.2% efficacy in preventing herpes zoster across all age groups ≥50 years 1
- For adults ≥70 years, pooled analysis shows 91.3% efficacy against herpes zoster and 88.8% against post-herpetic neuralgia 1
No Upper Age Limit
The evidence clearly shows:
- Older guidelines from 2012-2014 recommended starting at age 60, though the vaccine was FDA-approved from age 50 2, 3, 4
- Current guidelines have no upper age cutoff—the vaccine remains effective and safe in the oldest age groups studied 1
- Protection persists above 83.3% for up to 8 years and remains at 73% at 10 years post-vaccination 1
Important Clinical Considerations
Vaccine Preference
RZV (Shingrix) is strongly preferred over the older live-attenuated vaccine (Zostavax/ZVL) because:
- Superior efficacy: RZV shows >90% efficacy vs. ZVL's 51-70% (age-dependent) 1
- Longer-lasting protection: RZV maintains efficacy while ZVL wanes significantly over time 1
- ZVL is no longer recommended in the US and many Western European countries 1
Special Populations
Immunocompromised Adults:
- RZV is recommended for immunocompromised adults aged ≥19 years (note the lower starting age) 5, 6
- This includes those with HIV, cancer, autoimmune diseases, or on immunosuppressive therapy
- RZV is a non-live vaccine, making it safe for this population 5
Common Pitfall to Avoid
Do not delay vaccination in older adults thinking they are "too old" to benefit—the vaccine remains highly effective even in those ≥70 years, and this population faces the highest risk of herpes zoster complications including post-herpetic neuralgia 1.
Dosing Schedule
Expected Side Effects
Patients should be counseled that RZV causes more injection site reactions (9.5% grade 3) and systemic symptoms (11.4% grade 3) compared to placebo, but serious adverse events and deaths are not increased 1. These reactions, while uncomfortable, should not deter vaccination given the substantial protection against a painful and potentially debilitating disease.